|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by Wells Fargo on November 24, 2021. The analyst firm set a price target for 58.00 expecting HALO to rise to within 12 months (a possible 71.34% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $33.85 last updated Fri Nov 26 2021 18:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics’s $Q4 earnings are confirmed for after-market on February 22, 2022.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.